Identitication of two amino acid residues on Ebola virus glycoprotein 1 critical for cell entry

被引:31
作者
Mpanju, Onesmo M.
Towner, Jonathan S.
Dover, Jason E.
Nichol, Stuart T.
Wilson, Carolyn A.
机构
[1] US FDA, Ctr Biol Evaluat & Res, Div Cellular Tissue & Gene Therapies, Gene Transfer & Immunogenic Branch, Bethesda, MD 20892 USA
[2] Ctr Dis Control & Prevent, Special Pathogens Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30329 USA
关键词
filovirus; ebolavirus; glycoprotein; viral entry; mutagenesis;
D O I
10.1016/j.virusres.2006.06.002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Using site-directed mutagenesis and retroviral vector pseudotyping of the wild type or mutated glycoprotein of Zaire ebolavirus (ZEBOV), we analyzed 15 conserved residues in the N-terminus of the filovirus glycoprotein 1 (GP1) in order to identify residues critical for cell entry. Results from infectivity assays and Western blot analyses identified two phenylalanine residues at positions 88 and 159 that appear to be critical for ZEBOV entry in vitro. We extended this observation by introduction of alanines at either position 88 or 159 of Ivory Coast Ebolavirus (CIEBOV) and observed the same phenotype. Further, we showed that introduction of each of the two mutations in a recombinant full-length clone of ZEBOV (Mayinga strain) that also carried the coding sequence for GFP could not be rescued, suggesting the mutants rendered the virus non-infectious. The two phenylalanines that are critical for both ZEBOV and CIEBOV entry are found in two linear domains of GP1 that are highly conserved among filoviruses, and thus could provide a target for rational development of broadly cross-protective vaccines or antiviral therapies. Published by Elsevier B.V.
引用
收藏
页码:205 / 214
页数:10
相关论文
共 29 条
[1]  
Feldman D S, 1993, J Orthop Trauma, V7, P1, DOI 10.1097/00005131-199302000-00001
[2]   CHARACTERIZATION OF FILOVIRUSES BASED ON DIFFERENCES IN STRUCTURE AND ANTIGENICITY OF THE VIRION GLYCOPROTEIN [J].
FELDMANN, H ;
NICHOL, ST ;
KLENK, HD ;
PETERS, CJ ;
SANCHEZ, A .
VIROLOGY, 1994, 199 (02) :469-473
[3]  
Feldmann H, 1999, ARCH VIROL, P159
[4]  
FINER MH, 1994, BLOOD, V83, P43
[5]   Covalent modifications of the Ebola virus glycoprotein [J].
Jeffers, SA ;
Sanders, DA ;
Sanchez, A .
JOURNAL OF VIROLOGY, 2002, 76 (24) :12463-12472
[6]   Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses [J].
Jones, SM ;
Feldmann, H ;
Ströher, U ;
Geisbert, JB ;
Fernando, L ;
Grolla, A ;
Klenk, HD ;
Sullivan, NJ ;
Volchkov, VE ;
Fritz, EA ;
Daddario, KM ;
Hensley, LE ;
Jahrling, PB ;
Geisbert, TW .
NATURE MEDICINE, 2005, 11 (07) :786-790
[7]   Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-Å resolution [J].
Malashkevich, VN ;
Schneider, BJ ;
McNally, ML ;
Milhollen, MA ;
Pang, JX ;
Kim, PS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (06) :2662-2667
[8]   Comprehensive analysis of Ebola virus GP1 in viral entry [J].
Manicassamy, B ;
Wang, JZ ;
Jiang, HQ ;
Rong, LJ .
JOURNAL OF VIROLOGY, 2005, 79 (08) :4793-4805
[9]   Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung [J].
Medina, MF ;
Kobinger, GP ;
Rux, J ;
Gasmi, M ;
Looney, DJ ;
Bates, P ;
Wilson, JM .
MOLECULAR THERAPY, 2003, 8 (05) :777-789
[10]   Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture [J].
Neumann, G ;
Feldmann, H ;
Watanabe, S ;
Lukashevich, I ;
Kawaoka, Y .
JOURNAL OF VIROLOGY, 2002, 76 (01) :406-410